RxDoctor Payments Data

Juan Carlos Caballero, MD

Dermatology · Warrenton, VANPI 1801068937

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,431 of the $13,751 with a category attached, or 83.1%. AbbVie accounts for 88.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $5,521 and has fallen 90.6% since, to $519 in 2025.

$13,751in general payments, 2019–2025

Across 112 payments — averaging $122.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$12K
  • Johnson & Johnson$388
  • Sun Pharmaceutical Industries Inc.$142
  • Almirall LLC$132
  • Lilly USA, LLC$119
  • Novartis$102
  • plus $665 from 14 others

What the payments were for

  • Speaking & faculty fees$11,43183%
  • Food & beverage$1,88214%
  • Education$4383%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,751 in reported general payments places this provider in the 85th percentile of 396 dermatology providers in Virginia.

See all dermatology providers in Virginia

Medicare billing

Part B allowed, 2024
$580,920
Medicare patients
1,529
Services billed
8,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast11$52,360
Clobetasol Propionate55$4,207
Ivermectin14$3,791
Metronidazole43$2,078
Clindamycin Phosphate18$1,970
Fluocinonide29$1,247
Doxycycline Hyclate39$923
Triamcinolone Acetonide73$760
Ketoconazole50$614
Gentamicin Sulfate12$436
Nystatin14$204
Mupirocin22$186
ValacyclovirValacyclovir Hcl13$146
Spironolactone11$143
Hydrocortisone13$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$58$52,36011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 396 dermatology providers in Virginia.

Other dermatology in Warrenton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →